



ALEXION BIOPHARMACEUTICAL INDUSTRY

# FELLOWSHIP PROGRAMS

GLOBAL MEDICAL COMMUNICATIONS–GLOBAL MEDICAL AFFAIRS

GLOBAL PATIENT SAFETY

GLOBAL REGULATORY AFFAIRS

GLOBAL VALUE, ACCESS & PRICING

US MEDICAL AFFAIRS

PHARMACEUTICAL DEVELOPMENT AND CLINICAL SUPPLY

**ALEXION**<sup>®</sup>  
AstraZeneca Rare Disease

▼ ULTOMIRIS IV for H  
Transplant-Associ  
Microangiopathy (H

Support Services

▼ KOSELUGO® (selumetinib) for  
Neurofibromatosis Type 1 (NF1) Plexiform  
Neurofibromas (PN) in adults

Bone  
Metabolism

▼ Anselamimab (CAEL-101) for AL Amyloidosis

Cardiology

▼ Acoramidis for Transthyretin Amyloid  
Cardiomyopathy (ATTR-CM)

Cardiology

Albie, one of our guiding stars

When Albie was born, his mom, Charlotte, said  
that he was "absolutely fine. Everything was fine  
for about two weeks."



USMA Journal Cl  
in 5 minutes  
Microsoft Teams f

Snooty

## ABOUT ALEXION

1992  
YEAR  
FOUNDED

30+  
YEARS OF  
LEADERSHIP IN  
RARE DISEASE



- ▼ ULTOMIRIS IV for H Transplant-Associated Microangiopathy (TAM)
- ▼ KOSELUGO® (selumetinib) for Neurofibromatosis Type 1 (NF1) Plexiform Neurofibromas (PN) in adults
- ▼ Anselamimab (CAEL-101) for AL Amyloidosis
- ▼ ...midis for Transthyretin Amyloidomyopathy (ATTR-CM)

# 2023 CONTENTS

- 04 About Alexion
- 08 Fellowship Program Overview
- 10 Global Medical Communications-Global Medical Affairs
- 14 Global Patient Safety
- 16 Global Regulatory Affairs
- 18 Global Value, Access & Pricing
- 20 US Medical Affairs
- 22 Pharmaceutical Development and Clinical Supply
- 26 MCPHS
- 28 Application Requirements

5 APPROVED THERAPIES

7 RARE DISEASES

## ABOUT

# ALEXION

### ALEXION HEADQUARTERS

Alexion is headquartered in Boston, Massachusetts. Each fellowship program is two years in duration and most will be based in Boston.



Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases.

Our mission is to transform the lives of people affected by rare diseases through the development and delivery of innovative medicines, as well as supportive technologies and healthcare services.

At Alexion, we invest in and value people who believe in the importance of our mission and understand what it takes to deliver on it. Our culture is rooted in integrity, inclusiveness, and our dedication to joining and supporting the communities in which we live and work.

Today, our internal research efforts focus on leveraging our 30+ years of leadership in rare disease. This knowledge allows us to innovate and evolve into new areas where there is great unmet need and opportunity to help patients and families fully live their best lives. Our development efforts focus on the core therapeutic areas of haematology, nephrology, neurology, metabolics, bone metabolism, cardiology and ophthalmology.

We continue to lead in complement science by exploring new targets, and expand beyond complement to strengthen our clinical-stage pipeline through internal and external development opportunities in our core areas.

Every day, people living with rare diseases, their caregivers, and families face fears of the unknown with courage, tenacity, and grace; we believe it is our responsibility to listen to, understand, and change their lives.



The collaborative, engaging, and innovative culture within this company inspires a program that empowers fellows to maximize their potential within this field.”

JULIA SETTLER, PharmD, MBA

## OUR VALUES

Our culture values are the guiding principles behind why and how we do our important work

The work we do is guided by people affected by rare diseases. We are driven to continuously innovate and create meaningful value in all we do to help patients and families fully live their best lives.



WE FOLLOW  
THE SCIENCE



WE PUT  
PATIENTS FIRST



WE PLAY  
TO WIN



WE DO THE  
RIGHT THING



WE ARE  
ENTREPRENEURIAL

# OUR COMMITMENT TO INCLUSION & DIVERSITY

We create a working environment where every employee has a sense of belonging, regardless of gender, race, ethnicity, religion, age, disability status or sexual orientation.



This includes equitable compensation, benefits and opportunities for development and advancement.


We believe that inclusion is a right and diversity is a strength. Both make a fundamental contribution to the success of our company because innovation requires breakthrough ideas that only come from a diverse workforce empowered to challenge conventional thinking.

We believe our shared creativity unlocks challenges and brings new solutions. Incorporating Inclusion and Diversity (I&D) across all aspects of our organisation is imperative to innovating for patients, continuous learning, and growing as individuals and as a company.

Inclusion and diversity is one of the foundations of our People strategy — driving innovation, engagement and a sense of connection and belonging. We focus on four areas:


- **EMPOWERING** inclusive leadership
- **FOSTERING** an environment where we each speak our minds
- **BUILDING** and sustaining a diverse leadership and talent pipeline
- **CONTRIBUTING** to society, which includes our commitments to supplier diversity, clinical trial diversity, and health equity

# THERAPEUTIC AREAS




Neurology  
Ophthalmology

**CHELSEY**  
LIVING WITH NEUROMYELITIS  
OPTICA SPECTRUM DISORDER



Haematology  
Nephrology

**VICTOR**  
LIVING WITH PAROXYSMAL  
NOCTURNAL HEMOGLOBINURIA



Metabolics  
Bone Metabolism

**ARIA**  
LIVING WITH HYPOPHOSPHATASIA



Cardiology

ALEXION/MCPHS

# FELLOWSHIP PROGRAM

Alexion, in collaboration with MCPHS, is pleased to offer six unique postdoctoral fellowship programs to candidates obtaining a Doctor of Pharmacy. Through this experience, fellows will gain exposure to the biopharmaceutical industry, enhancing their understanding and establishing a foundation as an industry professional.

## GLOBAL MEDICAL COMMUNICATIONS- GLOBAL MEDICAL AFFAIRS

**3 POSITIONS**

## GLOBAL PATIENT SAFETY

**1 POSITION**

## GLOBAL REGULATORY AFFAIRS

**1 POSITION**

## GLOBAL VALUE, ACCESS & PRICING

**1 POSITION**

## US MEDICAL AFFAIRS

**1 POSITION**

## PHARMACEUTICAL DEVELOPMENT AND CLINICAL SUPPLY

**1 POSITION**





Alexion's commitment to serving patients with rare diseases is what initially drew me to the company. The work culture here is extremely inclusive, welcoming, and motivating."

MAYA OSMAN, PharmD



# GLOBAL MEDICAL COMMUNICATIONS— GLOBAL MEDICAL AFFAIRS

## 2-YEAR PROGRAM



**MEDICAL INFORMATION  
9 MONTHS**

**MEDICAL REVIEW  
9 MONTHS**

**ELECTIVE  
6 MONTHS**

This two-year program offers fellows the opportunity to gain extensive experience within Global Medical Communications and Global Medical Affairs in a fast-paced and patient-centric biopharmaceutical company focused on developing and delivering life-changing therapies for patients with rare diseases.

Second year fellows will have opportunities to choose an elective rotation. Fellows will be encouraged to identify areas of interest and seize opportunities to engage in impactful, longitudinal projects in various departments.



**“Global Medical Communications continues to play a critical role in raising awareness of the challenges of living with a rare disease.”**

**CHRISTOPHE HOTERMANS**

### **FOCUSED DEVELOPMENT**

- Communication and Interpersonal Skills
- Medical and Scientific Expertise
- Strategic Thinking
- Collaborating for Solutions
- Project Management and Prioritization
- Driving for Results

## Dear Prospective Fellow,

Thank you for your interest in the Alexion Fellowship Program in collaboration with Massachusetts College of Pharmacy and Health Sciences (MCPHS) University.


As we pursue our mission of transforming lives through the development of innovative therapies for patients with rare diseases in neurology, haematology, and other therapeutic areas—the Global Medical Affairs team, including Global Medical Communications, continues to play a critical role in serving these patients and raising awareness of the challenges of living with a rare disease.

I wish you the best of luck as you explore the available opportunities and encourage you to consider the Alexion Fellowship Programs.

Sincerely,

### **CHRISTOPHE HOTERMANS, MD, PhD**

*Senior Vice President, Head of Medical Affairs,  
Alexion, AstraZeneca Rare Disease*



## GLOBAL MEDICAL COMMUNICATIONS– GLOBAL MEDICAL AFFAIRS FELLOWSHIP TEAM

### **DIANE LAWSON, PharmD, RPh**

FELLOWSHIP PROGRAM DIRECTOR; GMC-GMA PROGRAM LEAD



Diane Lawson is the therapeutic area lead for the Neurology Medical Information-Medical Review team, partnering with US and Global functions. Diane's 20-year pharmaceutical experience has consisted of various leadership positions managing medical publications, medical information, and

R&D programs designed to advance biopharmaceutical careers for physicians and pharmacists new to industry. Prior to joining Alexion in 2018, Diane received her Bachelor of Science in Pharmacy at the University of Iowa, and her Doctor of Pharmacy from the University of Florida.

### **SASHA W. GALLAGHER, PharmD**

GMC-GMA PRECEPTOR



Sasha W. Gallagher is the therapeutic area lead for Metabolics within the US & Global Medical Information-Medical Review team at Alexion. Sasha has more than 15 years of pharmaceutical industry experience in roles of increasing responsibility related to clinical research, pharmacovigilance, medical information and medical review.

Sasha received her Bachelor's degree in Neuroscience from the University of Virginia and her Doctor of Pharmacy degree from Virginia Commonwealth University.

### **AHSAN JAMIL, PharmD**

GMC-GMA PRECEPTOR



Ahsan Jamil is the Therapeutic Area lead for Hematology & Nephrology within the US & Global Medical Information-Medical Review team. Ahsan has experience across various medical affairs roles and companies within the pharmaceutical industry. Prior to joining Alexion, his experience spanned several therapeutic

areas including oncology, hematology, cardiovascular, metabolics, biosimilars, and general medicines. Ahsan received his Doctor of Pharmacy from Rutgers University.

## FELLOWSHIP ROTATION 1

# GLOBAL MEDICAL INFORMATION

- **DEVELOP** and deliver high-quality, balanced, and timely written or verbal medical and scientific information in response to requests from health care professionals and consumers
- **CONTRIBUTE** to the development and maintenance of medical information written responses to address a vast array of inquiries to aid HCPs in clinical decision-making
- **SUPPORT** Medical Information booth activities prior to, during, and after professional scientific meetings and medical congresses
- **PARTNER** with cross-functional teams (e.g., Medical Affairs, Marketing, Clinical Development, Competitive Intelligence, Pharmacovigilance, Biostatistics, Medical Training, Corporate Communications) to contribute to product launch activities, development of competitive readiness resources, and creation of medical information deliverables aligning with medical strategic initiative

## ELECTIVE ROTATION DESCRIPTION

Fellows will have the opportunity to choose an elective rotation. Rotational areas may include:

- Medical Science Liaison
- US Medical Affairs
- Regulatory Affairs
- Clinical Development
- Health Economics Outcomes Research
- Global Patient Safety
- Scientific Communications
- Medical Training



The team at Alexion is actively engaged in my success and ensuring that I feel comfortable and confident with my therapeutic area”

THO DAO, PharmD

## FELLOWSHIP ROTATION 2

# GLOBAL MEDICAL REVIEW

- **DEVELOP** strategic partnerships with stakeholders from Medical Affairs, Clinical Development, Regulatory Affairs, Legal, Marketing, Compliance, and others to support the development and approval of robust, compelling, and accurate materials for healthcare providers, patients, and other groups
- **PROVIDE** comprehensive medical review and consultative expertise for product launch campaigns, congress symposia, speaker decks, and other materials used by field Medical Affairs and Commercial colleagues
- **COLLABORATE** with subject matter experts across Medical Affairs and Clinical Development to ensure the content of promotional and medical materials is scientifically appropriate, clinically relevant, and aligned to company strategy
- **PARTICIPATE** in live meetings of Promotional and Medical Review Committees, which are comprised of a collaborative, cross-functional team including Medical, Legal, and Regulatory review colleagues and Commercial or Medical content creators



## GLOBAL MEDICAL COMMUNICATIONS–GLOBAL MEDICAL AFFAIRS FELLOWSHIP TEAM

### TIMOTHY O'NEILL, PharmD

SECOND-YEAR GMC-GMA FELLOW




“In my time as a fellow I have met so many people that have volunteered their time proactively to help me get started, and I know that I will foster many great relationships here. You feel like the team will help you become extremely well-

versed in your therapeutic area, and when that area has a very active portfolio and promising pipeline of products for diseases without many options, you can always be excited about what there is to learn next.”

### MAYA OSMAN, PharmD

SECOND-YEAR GMC-GMA FELLOW



“Alexion’s commitment to serving patients with rare and debilitating diseases is what initially drew me to the company. The work culture here is extremely inclusive, welcoming, and motivating. With the help of my outstanding preceptors, I have been

able to make a smooth transition from being a pharmacy student to a pharmacist working in industry. I am glad to be completing my fellowship at a company where I feel supported, connected, and can grow professionally.”

### PAUL PARK, PharmD

SECOND-YEAR GMC-GMA FELLOW



“The amount of incredible support I received from my colleagues and peers helped me fit right into the team. The environment is amazing and anytime I had a question, my Alexion co-workers would always set aside time to help and collaborate. The work I do feels impactful

and essential, and it is amazing working in a company that matches my commitment and drive for serving patients with extremely rare diseases.”

### JULIA SETTLER, PharmD, MBA

FIRST-YEAR GMC-GMA FELLOW



“Alexion’s devotion to improving the lives of patients living with rare diseases is fundamental to the fulfilling nature of this fellowship program. Since the start of my fellowship, everyone here at Alexion has been exceptionally welcoming and eager to share their expertise/guidance.

The collaborative, engaging, and innovative culture within this company inspires a program that empowers fellows to maximize their potential within this field. In my short time as an Alexion fellow, I have been consistently impressed with Alexion’s commitment to excellence and dedication to improving the lives of patients around the globe.”

### CHRISTINA MILLER, PharmD

FIRST-YEAR GMC-GMA FELLOW



“In the beginning of my time at Alexion, I was instantly inspired by the dedication to improving the lives of patients with rare diseases among the members of the company. The collaborative and welcoming environment has allowed me to see that I have a

valuable role on the team. The design of the fellowship provides experiences in several functions within Medical Affairs with guidance from industry professionals. I am grateful to have the opportunity to complete my fellowship with a team that is incredibly supportive of my development and committed to providing me with a versatile experience in the pharmaceutical industry.”

### THO DAO, PharmD

FIRST-YEAR GMC-GMA FELLOW




“While I am in the early stages of my journey here at Alexion, from the first day, everyone has shown me a great amount of support in helping me prepare for the fellowship. The team at Alexion is actively engaged in my success and ensuring that I feel comfortable and confident with my

therapeutic area. Alexion’s diverse pipeline and inclusive work environment has given me the tools to be able to serve our patients and make an impact in rare disease.”

# GLOBAL PATIENT SAFETY

## 2-YEAR PROGRAM

### ONBOARDING ~ 6 WEEKS



\*Dependent upon interest and availability, the fellow may elect to rotate through additional areas within Safety or other functional areas (eg. Regulatory Affairs, Medical Affairs, Global Medical Communications)

Global Patient Safety (GPS) provides continuous and proactive assessment, management and communication of patient risks associated with Alexion products. The department aims to optimize patient safety while complying with global regulatory requirements, being supported by an agile organization, and exemplifying rigorous process management.

### THE ALEXION GLOBAL PATIENT SAFETY FELLOWSHIP WILL GIVE THE FELLOW THE OPPORTUNITY TO:

- **DEVELOP** the ability to think strategically and understand the role of Patient Safety in the lifecycle of products
- **UNDERSTAND** the benefit/risk balance of orphan drugs designed to treat devastating diseases
- **CULTIVATE** and utilize knowledge in international pharmacovigilance regulations and guidelines, to increase process effectiveness
- **PARTICIPATE** and engage in cross-functional team projects involving Commercial, Marketing, Medical Affairs and Regulatory Affairs to disseminate Global Patient Safety messages
- **UTILIZE** scientific knowledge and research skills to support safety surveillance and risk management decisions
- **DEVELOP** skills to communicate complex safety messages cross-functionally and influence decision making

### KEY ASPECTS OF THE PROGRAM:

- This two-year program in the Global Patient Safety department at Alexion is designed to equip the fellow with the proper skillset to progress and have a successful career in the pharmaceutical industry
- The program consists of core experiences within Global Patient Safety and features the opportunity for the fellow to complete an elective rotation, within a separate functional area, depending on the interest of the fellow
- The program affords the fellow the unique opportunity to work on products that treat ultra-rare disease states with no other treatment options

**“The work that we do for rare disease patients has been very rewarding and I am in awe of the passion that the company shows for these patients.”**

JANKI PATEL, PharmD, RPh

**Annually,** Alexion, AstraZeneca Rare Disease, offers a fellowship that prepares the next generation of patient safety and pharmacovigilance professionals to be a part of innovative therapy development to transform lives globally. I'm excited to welcome our next fellow!

This fellowship offers a unique opportunity for pharmacists to get exposure to the patient safety function, covering all therapeutic areas and all life cycles of Alexion products. Fellows will interact with many other cross functions including clinical development, medical affairs, quality and regulatory affairs for a complete view of the critical role of patient safety.

We are looking for colleagues who, like us, are passionate about reducing the suffering for those with rare and underserved diseases. Patient Safety improves lives of those living with rare diseases by optimally analyzing, understanding, and managing the benefit risk of these medicines including potential and confirmed adverse reactions and other risks associated with the use of our life-changing and life-saving therapies.

### **ARSHAD MUJEEBUDDIN, MD**

*Vice President of Patient Safety  
Alexion, AstraZeneca Rare Disease*



## **GLOBAL PATIENT SAFETY FELLOWSHIP TEAM**

### **CYNTHIA CARILLO-INFANTE, MD, PhD**

GLOBAL PATIENT SAFETY PROGRAM LEAD



Cynthia Carrillo-Infante is a Physician Scientist with 15 years of industry experience in Pharmacovigilance overseeing safety of products throughout their lifecycle. Her expertise includes safety of small molecules and monoclonal antibodies in a broad range of therapeutic areas (neurology, immunology, infectious diseases, hematology). Cynthia joined Alexion in 2016 and currently serves as Senior Medical Director in Global Patient Safety within the complement therapeutic area. Prior to joining Alexion, Cynthia worked at Biogen and Vertex Pharmaceuticals where she served as the safety physician lead for several products in development and on the market. Cynthia received her MD from the Panamerican University in Mexico City, Mexico and her PhD in molecular pathology from the University of Siena, Italy.

### **ASHLEE HORGAN, PharmD, RPh**

GLOBAL PATIENT SAFETY PROGRAM LEAD



Ashlee Horgan is a Director, Safety Scientist in the Global Patient Safety team at Alexion. While actively reviewing the safety profile of multiple clinical development and marketed products to ensure that their benefit/risk profiles remain positive, Ashlee also leads patient safety process improvements to stay on top of evolving global regulations. Prior to joining Alexion, Ashlee worked in Drug Safety at Takeda Pharmaceuticals, and also spent time at Sanofi Genzyme where she completed a PharmD fellowship program and also worked as a Safety Scientist. Ashlee received her Doctor of Pharmacy from Albany College of Pharmacy and Health Sciences and her Graduate Certificate in Regulatory Affairs from Massachusetts College of Pharmacy and Health Sciences.

### **JANKI PATEL, PharmD, RPh**

SECOND-YEAR GLOBAL PATIENT SAFETY FELLOW



“As someone with no prior drug safety experience, the GPS team at Alexion has given me many learning opportunities and has helped me build a strong foundation in drug safety through connecting with experts in the field. Each person on the patient safety team wants me to succeed and makes themselves available to me for any questions.”

### **ROSETTA TOLLEY, PharmD**


FIRST-YEAR GLOBAL PATIENT SAFETY FELLOW



“I'm so excited to be a new member of Alexion's Global Patient Safety team where I can utilize my education to the highest degree to protect patients. Although I have been with the company a short time, I've felt incredibly welcomed by the team and am excited to continue to grow my relationships within the pharmaceutical industry.”

# GLOBAL REGULATORY AFFAIRS

## 2-YEAR PROGRAM



Regulatory Affairs (RA) a function within Alexion's Development, Regulatory and Safety organization, is responsible for the design and execution of innovative regulatory strategies that drive the advancement and approval of their products to serve patients. Through partnership with external stakeholders, RA colleagues make a positive contribution to the global regulatory environment and provide ongoing support of products that span the development cycle, with the highest degree of regulatory compliance.

The Alexion RA fellowship is designed to provide the fellow with hands-on exposure to a multitude of functions or specialties within RA and across products in the Hematology, Bone and Metabolics, Nephrology, and Neurology therapeutic areas. The fellow will have the opportunity to build a broad, robust foundation as a regulatory professional while directly contributing to the development of Alexion's products and the patients they serve. Throughout the program, the fellow will have the ability to tailor the program to their unique interests and overall professional development needs.

The fellow will be assigned to project teams and will work with designated RA function preceptors throughout three, 6-month core rotations in various sub-functions within regulatory. The fellow will also be given the opportunity of rotating through an additional sub-function in Regulatory Affairs of their choice.

### CORE ROTATIONS INCLUDE:

- Development Strategy
- Chemistry, Manufacturing, and Controls (CMC)
- Global Advertising and Promotional Compliance

Additionally, the fellow will have the opportunity to extend one or more of the core rotations, or select an elective, 6-month rotation within RA. Rotational areas may include:

- Regulatory Labeling
- Regulatory Intelligence
- Regulatory Operations
- Regulatory Affairs Marketed Products Strategy



**Regulatory affairs is a key strategic partner to health authorities and various functional teams within the company. We work across the drug development spectrum from research to post-marketing setting, ensuring that what we do every day brings life-changing therapies to patients."**

SARAH RHEE



## The Global Regulatory Affairs (GRA)

fellowship, which sits within the Regulatory Affairs (RA) group, has recruited and retained Pharmacy trainees across different regions for more than a decade and this fellowship program is an important step towards bringing in talented fellows to learn and acquire experience in the regulatory profession. In RA, we help Alexion shape the drug development story, translating our impactful science into innovative regulatory strategies to gain approval for treatments for patients with high unmet medical need, with the highest quality standards.

We champion diversity and inclusion in our teams, which are so important to foster innovation and develop new solutions for patients. We work across the drug development spectrum, ensuring that what we do every day will contribute to developing and bringing life changing therapies and improve the lives of patients and their families – all by a team of just over 200 people spread across 17 countries.

We are keen on inspiring and being inspired by Pharmacy Fellows who will help us achieve these goals! If you love learning and developing yourself through teamwork, if you are passionate about life sciences and the impact R&D can bring to patients suffering from rare diseases, this fellowship program is a unique opportunity for you!

### SARAH RHEE, MS

*Vice President, Head of Alexion Regulatory Affairs*



## GLOBAL REGULATORY AFFAIRS FELLOWSHIP TEAM

### JETHRO EKUTA, DVM, PhD, RAC, FRAPS

GLOBAL REGULATORY AFFAIRS PROGRAM LEAD



Jethro is a Vice President, Global Regulatory Affairs and US Lead at Alexion. He is an accomplished pharmaceutical executive with over 25 years of experience. Before he joined industry, Jethro was a Staff Fellow and Clinical Pharmacology Reviewer at the US Food and Drug Administration (FDA). Jethro holds the degree of Doctor of Veterinary Medicine (DVM) and received his Doctor of Philosophy (PhD)

in Pharmacology and Toxicology from the University of Mississippi. He is certified in Regulatory Affairs (RAC) and is a Fellow of the Regulatory Affairs Professionals Society (FRAPS). He currently serves as President, Board of Directors Regulatory Affairs Professionals Society (RAPS).

### ERICA LEE, RAC

GLOBAL REGULATORY AFFAIRS PRECEPTOR



Erica is a Director in the Global Regulatory Affairs, Development Strategy group at Alexion. She is the global regulatory lead for programs in the Hematology/Nephrology therapeutic areas. She has more than 15 years of pharmaceutical experience in roles related to assay development and Regulatory strategy. Prior to Alexion, Erica worked at Shire Pharmaceuticals and Syntimmune, Inc. leading CMC

strategy for rare diseases. Erica received her Bachelor of Arts in Biology and Chemistry at Clark University.

### MARK ZAPPACOSTA

GLOBAL REGULATORY AFFAIRS PRECEPTOR



Mark is currently an Associate Director in the Global Regulatory Affairs, Development Strategy group at Alexion. He is the global regulatory lead for programs in the Bone Metabolism therapeutic area. Mark has over a decade of industry experience spanning from Biomanufacturing, Quality Assurance, Clinical Supply, and numerous areas of Regulatory Affairs. After finishing his MS at Temple University School of

Pharmacy in Regulatory Affairs and Quality Assurance, he remains active in his post-graduate education receiving certifications in Clinical Trial Management, Drug Development, and Advanced Regulatory Affairs.

### BRIAN ARANA-MADRIZ, PharmD

SECOND-YEAR GLOBAL REGULATORY AFFAIRS FELLOW



“The opportunity to rotate through core functional areas within Regulatory Affairs is incredibly unique. It allows me to gain experience in multiple Regulatory functional areas, leveraging these experiences to become a well-rounded Regulatory Affairs professional. The culture at Alexion is contagious, working with passionate and driven individuals invested in delivering transformative

therapies to patients worldwide. My time at Alexion thus far has shown me that I am surrounded by individuals who care for my overall professional development.”

### MORGAN LOH, PharmD

FIRST-YEAR GLOBAL REGULATORY AFFAIRS FELLOW



“This program is especially unique by affording its fellows a rotational opportunity within key functional areas in Regulatory Affairs. It allows you to cultivate your regulatory knowledge and experience in multiple functional areas, providing a pathway to becoming a well-rounded regulatory professional. Working at Alexion grants you the privilege of collaborating with adept, passionate

individuals invested in expanding access to novel medicines and your professional growth. I feel incredibly fortunate to be working alongside those committed to serving their patients.”

# GLOBAL VALUE, ACCESS & PRICING

## 2-YEAR PROGRAM

### GLOBAL VALUE, ACCESS & PRICING AND HEOR ENRICHMENT OPPORTUNITIES

- Input into protocol development
- Global Value Dossier & Value Story
- Strategic Life Cycle Management
- Evidence Generation Plan
- Economic model (CEA & BIM) development

MCPHS in collaboration with Alexion, AstraZeneca Rare Disease is offering fellowship experience within Global Value, Access & Pricing (GVAP) with an enriched Health Economics & Outcomes Research (HEOR) experience.

AstraZeneca's Rare Disease GVAP team is seeking a fellow to be part of a dynamic and growing team working in the metabolic portfolio. This is a strategic role leveraging your understanding and application of global healthcare, HTA system knowledge, competitive insights, and clinical background to shape market access, pricing and reimbursement success for critical product launches and indications.

This fellowship provides a unique opportunity to develop an expertise in the cross-section of GVAP & HEOR. Global market access and health economics are complimentary functions with HTA/payers as the core stakeholder and this fellowship is designed to combine the strategic components of HEOR and apply them to real-world global market access problems. As a fellow you will learn to lead the development and execution of value, access, and price strategies for launch assets to support patient access to our medicines. As key parts of the development team, we help shape the clinical development program, develop value propositions that help inform evidence generation activities, and establish pricing recommendations for products in our portfolio.

### FOCUSED OBJECTIVES VALUE, ACCESS & PRICING

- **SUPPORT** development of differentiated target product profile that fulfills cross stakeholder needs aligned to robust value proposition
- **DEVELOP** global pricing and reimbursement (P&R) strategies and framework in close collaboration with launch and program teams
- **CREATION** and roll out of value, and access communication tools and materials to support local P&R submissions and negotiations
- **CULTIVATE** understanding of global health care, HTA systems, and latest developing trends especially within rare disease

### FOCUSED OBJECTIVES HEALTH ECONOMICS & OUTCOMES RESEARCH

- **COMPREHENSIVE** understanding of what evidence payers value across market/payer archetypes
- **FUNDAMENTALS** of economic modeling bridging to appreciation of level of evidence needed from payer perspective
- **INFLUENCING** trial design, outcomes, and endpoint strategy to support payer needs
- **EXPOSURE** to different methodologies to quantify and fill evidence gaps including burden of disease & unmet need

**I am thrilled** that the Global Value, Access & Pricing team has initiated a new fellowship program in collaboration with MCPHS. I am committed to mentoring new talent within our organization and this accelerated development program will offer a hands-on opportunity to gain a skillset needed to become a future market access leader.

We at Alexion, AstraZeneca Rare Disease are driven by improving the lives of the patients we serve and are positioned to be leaders within the market access rare disease space. Rare disease patients have unique access challenges that push our team to find innovative and sustainable solutions. Join a highly valued, strategic team that is fundamental in realizing the potential of our life-changing medicines. It's through our work that AstraZeneca is able to ensure the right access is provided to our transformative medicines.

#### **LUKASZ JARZYNA**

*Vice President of Global Value, Access & Pricing  
Executive Sponsor, Alexion, AstraZeneca Rare Disease*



**Join a highly valued, strategic team that is fundamental in realizing the potential of our life-changing medicines.”**

**LUKASZ JARZYNA**

## **GVAP & HEOR TEAM**

### **SIMU THOMAS, M Pharm, MS, PhD**


**VICE PRESIDENT OF GLOBAL HEALTH ECONOMICS & OUTCOMES RESEARCH  
EXECUTIVE SPONSOR**



Simu is the VP and Global Head of HEOR at Alexion Pharmaceuticals. He has authored more than 35 manuscripts and 75 congress presentations and co-authored book chapters in the field of Health Economics. Simu holds a PhD in Pharmaceutical Economics from the University of Maryland and MS in Pharmacy Administration from the University of Toledo and Pharmacy degrees. Simu also serves as Adjunct Assistant Professor at University of Maryland and Rutgers University of New Jersey.

### **JENNIFER POCOSKI, PharmD**

**GLOBAL VALUE, ACCESS & PRICING HEAD, META+LEAD**



Jennifer is currently the Global Value, Access & Pricing Head for the metabolic portfolio. Jennifer has held several positions within the access and health economics over the last 15 years. She completed her two-year fellowship at Bayer Pharmaceuticals in Medical Affairs and Health Economics. She received her PharmD from Northeastern University.

### **KRYSTAL HUEY, PharmD, MS**


**GLOBAL VALUE, ACCESS & PRICING PRECEPTOR**



Krystal is currently the Global Value, Access & Pricing lead for the Amyloidosis programs. She completed her two-year fellowship at Celgene/BMS in HEOR and GVAP. She received her PharmD from Northeastern University and her MS in Health Outcomes, Policy and Economics from Rutgers University.

### **CRAIG WAKEFORD, BA, MA**

**GLOBAL HEALTH ECONOMICS OUTCOMES RESEARCH, META+ SENIOR DIRECTOR**



Craig is currently the Senior Director of HEOR at Alexion. He holds a B.A. in Economics from the University of Toronto and a Masters in Economics from the University of Ottawa. He has held multiple positions within HEOR and Access in the past 10 years across multiple therapeutic areas.

### **SAIRA JATOI, PharmD**

**FIRST-YEAR GVAP FELLOW**



“As the inaugural GVAP fellow at Alexion, I am grateful to be part of a team that is enthusiastic about providing me learning opportunities to develop professionally in the Market Access space. The HEOR enrichment aspect of the program gives me the chance to work cross-functionally and broaden my knowledge base. I am honored to be part of a team dedicated to aiding patients with rare diseases.”

# US MEDICAL AFFAIRS (USMA)

## 2-YEAR PROGRAM

### US MEDICAL AFFAIRS (USMA)

**US MEDICAL  
EXCELLENCE  
6 MONTHS**

**US MEDICAL  
DIRECTOR  
6 MONTHS**

**US MEDICAL  
SCIENCE LIAISON  
6 MONTHS**

**ELECTIVE  
6 MONTHS**

USMA is a rotational program with 6-month rotations in US Medical Excellence, US Medical Director, and US Medical Science Liaison positions. The schedule for core rotations will be individualized, to align the fellow with major developments within Alexion. The program also allows for a final 6-month elective rotation in any area the fellow desires.

### CORE ROTATION DESCRIPTIONS

#### US MEDICAL EXCELLENCE

- Develop and update scientific field materials under guidance of the medical communications leads
- Participate in the planning and execution of USMA activities at national medical congresses
- Identify, develop, and execute trainings needed across USMA to increase scientific knowledge and skill development
- Work on special projects as needed which further USMA and medical excellence strategic imperatives

#### US MEDICAL DIRECTOR

- Participate in cross-functional projects to create internal and external deliverables
- Support Medical Directors within a therapeutic area on tactical implementation of key program initiatives
- Contribute to the medical and regulatory review process of field medical and external resources
- Develop leadership skills and fundamental knowledge in the area of strategic planning within the Medical Affairs organization

#### US MEDICAL SCIENCE LIAISON

- Participate in Medical Science Liaison (MSL) onboarding and certification
- Provide support to national medical congresses and provide medical support via abstract coverage, booth staffing and Key Opinion Leader (KOL) engagement
- Actively participate with MSLs in their field engagements
- Observe and learn from USMA leadership

### ELECTIVE ROTATION DESCRIPTION

Additionally, the fellow will have the opportunity to extend one or more of the core rotations, or select an elective, 6-month rotation either within USMA or another functional area. Rotational areas may include but are not limited to:

- Regulatory Labeling
- Quality Affairs
- Global Medical Affairs
- Clinical Development
- Global Patient Safety (Pharmacovigilance)
- Commercial

## US MEDICAL AFFAIRS (USMA) TEAM

### MICHELLE CIAMBELLA, PharmD, RPh

US MEDICAL COMMUNICATIONS LEAD - NFI  
USMA FELLOWSHIP PROGRAM LEAD



Michelle graduated in 2020 from the University of Arizona and came to Alexion via a two-year fellowship in the GMC/GMA program. She has found a home in US Medical Affairs as the Medical Communications Lead for NFI. She

combines a passion for teaching and science to create best-in-class scientific educational content for HCPs. She is committed to the success of all fellows and can be found hosting learning opportunities.

### ALLEN HO, PharmD, RPh

MSL DIRECTOR - HEMATOLOGY/ NEPHROLOGY




Allen has 15 years of experience in the pharmaceutical industry working in medical affairs. As a past fellow, and a PharmD by training, Allen is passionate about mentorship and training the next wave of future medical affairs leaders. He is currently

the Director, MSL Lead for Hematology and Nephrology for the west and has over 12 years of experience as a MSL.

### SUSAN LENHART-HERMAN, PharmD, RPh, BCPS

US MEDICAL COMMUNICATIONS LEAD




Susan has worked in the pharmaceutical industry for over 20 years gaining a wide range of experiences in field-based medical affairs. In her current role as Associate Director, Medical Communications Lead-

Metabolics on the US Medical Excellence

team, she is committed to supporting the success of the field-based teams via the development of highly scientific and engaging resources aligned with medical affairs strategy. She has always had a passion for teaching and mentoring and is excited to champion the professional growth and development of the fellows.

### CHLOE SADER, PharmD, RPh

SENIOR MEDICAL DIRECTOR, USMA



Chloe has 14+ years of experience in the pharma/biopharma industry. Having started as an intern during pharmacy school, she subsequently charted the course through Global & US Medical Affairs to her current role as Senior Medical Director. In this role,

she is responsible for leading the strategic development and execution of the myasthenia gravis rare disease program in the US, working closely with cross-functional teams, global medical, and neurology field medical. Chloe enjoys serving as a mentor and helping individuals lean into their full potential.

### RADA ZUNICH, PharmD

US MEDICAL AFFAIRS FELLOW



This fellowship provides many diverse experiences, allowing fellows to rotate through the different teams within US Medical Affairs. The projects are meaningful and contribute to my development as a young professional in the pharmaceutical

industry. I appreciate the opportunities for collaboration across functional groups, as well as the mentorship within the USMA space. I am beyond grateful to work alongside incredible people who are dedicated to putting our patients first."



# PHARMACEUTICAL DEVELOPMENT AND CLINICAL SUPPLY

## 2-YEAR PROGRAM



The Pharmaceutical Development & Clinical Supply (PDCS) fellowship is designed to provide fellows the opportunity to collaborate cross-functionally, build leadership skills through applied, hands-on experience, and develop strong relationships with biopharmaceutical industry leaders. Through their participation, fellows will build their subject matter expertise and be committed partners in advancing Alexion's mission and values.

### **CORE ROTATIONS WILL INCLUDE BUT NOT LIMITED TO:**

- Drug substance/drug product manufacturing
- Supporting combination/ injectable products through the asset lifecycle
- Forecasting Investigational Medicinal Product (IMP) demands
- Partnering with internal and external stakeholders to support clinical trials

Fellows will be guided, mentored, and supported by the larger Alexion team. Specifically, they will have the guidance of preceptors, who have the experience of being both past PharmD fellows and members of the organization. In addition, fellows will serve as key partners in contributing to Alexion's strategic roadmap, a unique opportunity, which will continue to elevate Alexion as the leader in Product Development & Clinical Supply.

The two-year fellowship will be based out of New Haven, Connecticut. All rotational experiences will be in New Haven, with virtual engagements and projects available to global colleagues.

**At Alexion**, we are committed to building a world-class organization and our people are our greatest asset for creating those opportunities of growth, learning, and collaboration. Our partnership with MCPHS and its fellowship program is an exciting opportunity because it accelerates that impact and allows fellows to learn firsthand through supporting Alexion's clinical studies.

The mentorship and support that fellows will receive through this partnership is unparalleled and will showcase our great talent and commitment to individual learning and growth.

The Pharmaceutical Development and Clinical Supply team is committed to supporting Alexion's clinical studies with the highest level of service and treatment for our patients. Clinical Supply for rare disease indications present nuanced challenges that pave the way for innovative thinking. By joining Alexion, you will become part of a larger team and community, one steeped in patient-centered care and cutting-edge science.

**MARK SWIFT, PharmD, RPh, BS, JD**

*Senior Director of Clinical Supply Management, Global Operations, Alexion, AstraZeneca Rare Disease*



**By joining Alexion, you will become part of a larger team and community, one steeped in patient-centered care and cutting-edge science."**

**MARK SWIFT**

**PHARMACEUTICAL DEVELOPMENT AND CLINICAL SUPPLY FELLOWSHIP TEAM**

**RAYHAN SHAIKH, PharmD, BCSCP, RPh, MBA**

PHARMACEUTICAL DEVELOPMENT AND CLINICAL SUPPLY PROGRAM LEAD



Rayhan is an Associate Director in Clinical Supply Management and the PDSCS fellowship lead. Rayhan has 11+ years of clinical hospital experience as well as 7 years of global product development and clinical supply experience. He received his PharmD from the University of Connecticut and his MBA from the University of Rhode Island.

**CHRISTIN LABELLE, BA, MPH**

CLINICAL SUPPLY QUALITY LEAD



Christin is a Senior Specialist in Development Supply Quality and has 20 years of experience in the Pharma Industry. Her experience includes quality control/assurance, Pharmacovigilance, clinical research, and training. She received her MPH in Epidemiology from the Boston University School of Public Health and her BA in Neuroscience from Wheaton College.

**CRYSTAL MA, PharmD, RPh**


CLINICAL SUPPLY MANAGEMENT PRECEPTOR



Crystal is an Associate Director in Clinical Supply Management. Crystal worked as a Clinical Supply Manager at Merck KGaA and also spent time at Pfizer where she completed a 2-year post PharmD fellowship program in Clinical Supply Strategy and Management. Crystal received her PharmD from Purdue University College of Pharmacy.

**KATIRIA FLORES, BS, MS, PhD**

INJECTABLES DRUG PRODUCT DEVELOPMENT PRECEPTOR



Katiria is a Senior Scientist in the Injectables Drug Product Development. Katiria has 6 years of experience leading the clinical in-use compatibility studies. Her work has supported intravenous and subcutaneous drug product administration for 12 Alexion products in different cycles/phases. Katiria received her BS in Industrial Microbiology from the University of Puerto Rico and her MS and PhD in Physiology and Neurobiology from the University of Connecticut.

# REFLECTIONS FROM PAST FELLOWS

## GABRIELA MARCHEVA, PharmD 2017–2019

GLOBAL LIFE CYCLE MANAGEMENT DIRECTOR, IMMUNE THROMBOTIC THROMBOCYTOPENIA PURPURA AT SANOFI




“Through the two-year Alexion fellowship program, I was able to dive deep into a variety of meaningful projects with ambitious cross-functional teams, and the skills I started developing led me to where I am today in my current role. Active

involvement as a fellow is the key to success, and I strongly encourage taking every possible opportunity to lead projects and engage with team members.”

## ADAM QUICQUARO, PharmD 2018–2020

ASSOCIATE DIRECTOR, CLINICAL DEVELOPMENT SCIENCES AT ALEXION PHARMACEUTICALS



“The Alexion Fellowship program exposed me to a unique variety of cross-functional experiences that allowed me to develop a broad skillset which truly prepared me for my current role today. It also provided a stimulating work environment

that fostered my development as a professional and offered me the opportunity to serve rare disease patients with unmet medical needs.”

## MATTHEW LUEN, PharmD 2018–2020

SENIOR MANAGER, NEW PRODUCT GLOBAL MARKETING AT TOLMAR



“The Alexion fellowship program was a great opportunity to learn from and contribute to many different teams. Throughout my fellowship experience, I was able to work in both medical and commercial facing functions to solve

complex challenges, and ultimately provide the best solutions for patients.”

## KATIE WRAY, PharmD 2019–2021

DIRECTOR, MEDICAL AFFAIRS AT INOZYME PHARMA



“The Alexion GMC/GMA fellowship program allowed me to explore multiple functions while equipping me with the valuable skill sets that I use today, including cross-functional collaboration, project management, and communication of

scientific literature.”

## DIAN LIN, PharmD 2019–2021

SENIOR MANAGER, PAYER AND CHANNEL MARKETING AT BIOGEN




“The Alexion fellowship program has given me the unique opportunity to gain extensive experience in Medical Communications, Medical Affairs, and Payer Marketing. The rotational aspect of the fellowship has allowed me to build upon my

therapeutic area knowledge and core competencies to engage in cross-function medical and commercial activities that best serve patients with rare disease.”

## ALEXANDRA MARESH, PharmD, 2020–2022

SENIOR MANAGER IN GLOBAL MEDICAL INFORMATION AND MEDICAL REVIEW AT ALEXION



“Working with such passionate, motivated individuals throughout my fellowship solidified my desire to stay on as a full-time member of the team. I feel very fortunate to have gained experience learning from so many skilled mentors who always

provided me with support and encouragement.”

## CALANTHA YAN, PharmD 2020–2022

SENIOR SAFETY SCIENTIST AT SEAGEN




“The fellowship at Alexion, AstraZeneca Rare Disease was a great way to jumpstart my career in the pharmaceutical industry! The vast majority of my training was focused on drug safety, but I also gained cross-functional exposure during my time in the

program. These experiences strengthened my understanding of the role of the safety scientist as well as broadened my perspective of how the functional areas work together. The knowledge that I acquired shaped me into a valuable candidate upon the conclusion of my training.”

## CHRISTINE BORUNDA, PharmD 2020–2022

MEDICAL SCIENCE LIAISON IN NEUROLOGY AT ALEXION



“The opportunity to train hands-on in multiple functional areas allowed me to understand each team's role in the bigger scheme of things. This ultimately granted freedom to explore different types of work and align my interest to my current role.”





**MICHELLE CIAMBELLA, PharmD 2020–2022**

MEDICAL COMMUNICATIONS LEAD FOR META+ NFI-PN AT ALEXION



“The fellowship provided me with many meaningful experiences that prepared me for my full-time position. I’m grateful for the opportunity and all the friendships I made as well as the mentoring I received at Alexion.”

**MICHAEL MCDERMOTT, PharmD, RPh 2021–2023**


SENIOR MANAGER SAFETY SCIENTIST AT ALEXION



“The Patient Safety fellowship program was an invaluable experience that propelled my career in the biopharmaceutical industry. Through thoughtful mentorship and hands-on training, I gained the knowledge and skills needed to navigate the complex landscape of the pharmacovigilance, ultimately allowing me to have a meaningful impact on patient safety.”

**ALEXANDRA BURGER, PharmD 2021–2023**

SENIOR MANAGER, PAYER AND CHANNEL MARKETING AT ALEXION



“The Alexion, AstraZeneca Rare Disease fellowship program equipped me with valuable experiences that readied me for my full-time role. I feel incredibly lucky to have had the opportunity to learn from numerous mentors who consistently offered me unwavering support and motivation.”

# MCPHS



MCPHS provides an academic environment to guide and support fellows toward a successful career in the biopharmaceutical industry. As a private institution with a history of specializing in health sciences, MCPHS offers programs that embody scholarship, professional service, and community outreach.

Through the affiliation with MCPHS, fellows will have the opportunity to gain teaching and research experience in an academic setting. MCPHS faculty and company program leaders mentor fellows according to their scholarly and professional interests throughout the two-year program.

#### **AS AN ADJUNCT INSTRUCTOR AT MCPHS, FELLOWS WILL HAVE THE OPPORTUNITY TO:**

- **DEVELOP**, coordinate, and teach courses
- **CO-PRECEPT** pharmacy students on advanced experiential rotations
- **CREATE** and publish scholarly research and/or review articles
- **PRESENT** research at scientific and clinical meetings
- **PARTICIPATE** in professional development seminars with other MCPHS fellows

**The Alexion fellowship provides a unique opportunity to gain practical and valuable hands on experience that will allow for a successful and fruitful career in the biopharmaceutical industry.”**

**MATTHEW LUEN**  
*Past Fellow, Global Medical Communications–Global Medical Affairs*

# MCPHS TEAM

## AMEE MISTRY, PharmD

DIRECTOR OF THE POSTDOCTORAL BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM AND MCPHS FACULTY PRECEPTOR



Dr. Amee Mistry is a Professor of Pharmacy Practice and has been with MCPHS since 2006. Dr. Mistry earned her PharmD at the Albany College of Pharmacy and completed a PGY1 Community Practice Residency with Walgreens and MCPHS. In 2015, Dr. Mistry took over as Director of the MCPHS Biopharmaceutical Industry Fellowship program. She works directly with leaders in the area to continue to foster growth and development of the post graduate program, and to assist the fellows in attaining positions within the pharmaceutical industry. She also continues to teach and conduct scholarly work at MCPHS, trains pharmacists and student pharmacists nationally on immunizations, and is actively involved in her state and national pharmacy organizations.

## TRISHA LAPOINTE, PharmD, BCPS, FASHP

MCPHS FACULTY PRECEPTOR



Dr. LaPointe is a Professor of Pharmacy Practice at MCPHS. She earned her doctorate in pharmacy from Northeastern University in 2001 and completed her PGY-1 at Massachusetts General Hospital in Boston Massachusetts. Dr. LaPointe's current practice site at Lowell General Hospital where she sees patients in the inpatient care setting and mentors student pharmacists on inpatients general medicine rotations. Dr. LaPointe works with students, residents, and fellows to carry out scholarly pursuits.

## EWAN MCNICOL, PharmD

MCPHS FACULTY PRECEPTOR



Dr. McNicol is an Associate Professor of Pharmacy Practice at MCPHS where he maintains a practice site in ambulatory pain management at Atrius Health in Boston. He received his Doctor of Pharmacy degree from MCPHS in Boston in 2016. In addition, he has a Master's degree in Pain Research, Education and Policy from Tufts University from 2001. He conducts evidence-based reviews of analgesic interventions and outcomes for pain and related conditions, and has collaborated with current and former pharmacy fellows as a preceptor in this research.

## SHEILA SEED, PharmD, MPH, CTH®, AFTM RCPS(Glasg), RPh

MCPHS FACULTY PRECEPTOR



Sheila Seed is Professor and Chair for the Department of Pharmacy Practice at the Massachusetts College of Pharmacy and Health Sciences (MCPHS) School of Pharmacy Worcester/Manchester campuses. During the pandemic, she served as the University's COVID-19 Coordinator for all three campuses. She received her B.S in Pharmacy from the Massachusetts College of Pharmacy and Health Sciences, Boston, Masters of Public Health from the University of Massachusetts, Amherst and Doctor of Pharmacy (Pharm.D.) from Idaho State University. She has been a faculty member at MCPHS since 2001. Prior to her appointment, she worked in the community setting and as a pharmacy officer in the U.S. Air Force. Her areas of interests include public health, immunizations and travel medicine. She has a Certificate of Travel Health™ (CTH)®, and is an Associate Faculty Member of Travel Medicine at the Royal College of Physicians and Surgeons (Glasgow). She has served as the Secretary of Knowledge Management and the Chair of the AACP Public Health SIG and a past Coordinator of the APhA Immunization SIG. She continues to work with the SIG on updating the APhA Travel Health Quick Guide annually.

## YULIA MURRAY, PharmD

MCPHS FACULTY PRECEPTOR



Dr. Yulia Murray received a Doctor of Pharmacy degree from MCPHS University School of Pharmacy Worcester in 2007. Following graduation, Yulia completed a PGY-1 residency at Beth Israel Deaconess Medical Center (BIDMC). After completing residency year, Yulia took a position as a Clinical Medicine Pharmacist at Boston Medical Center and worked in that role for four years, while also staying on as a per-diem clinical pharmacist at BIDMC. In 2012, Yulia decided to pursue a career in academia and was offered a position as an Assistant Professor of Pharmacy Practice at MCPHS University School of Pharmacy Boston. Currently, Yulia serves as an Associate Professor of Pharmacy Practice with her clinical site at Newton-Wellesley Hospital.

## PHUNG ON, PharmD

MCPHS FACULTY PRECEPTOR



Dr. Phung On is an Associate Professor of Pharmacy Practice at MCPHS. She is the Academic Coordinator on the Boston Campus for the Biopharmaceutical Industry Fellowship program and the Coordinator of Diversity, Equity, and Inclusion for the School of Pharmacy – Boston. She earned her PharmD at MCPHS in Boston in 2013 and completed a PGY1 Pharmacy Practice Residency with a focus on ambulatory care, managed care, and transitions of care through the University of North Carolina in Chapel Hill and AccessCare, a network of Community Care of North Carolina. Dr. On maintains a clinical practice site in ambulatory care at Codman Square Health Center in Boston where she works collaboratively with the primary care team to manage patients' chronic diseases.

# APPLICATION REQUIREMENTS

## ELIGIBILITY

The MCPHS Biopharmaceutical Industry fellows will be selected on a nationally competitive basis. Applicants must have a Doctor of Pharmacy degree from an ACPE accredited college of pharmacy at the commencement of the program.

- Candidates must have strong written and verbal communication skills and a strong interest in pursuing a career within the biopharmaceutical industry.
- All candidates must have authorization to work in the United States throughout the duration of the one or two year fellowship. No visa sponsorship will be provided (i.e., TN, H-1B, STEM OPT, etc.).

## APPLICATION PROCEDURE

The MCPHS application portal (SMAApply) will open on **Monday October 2nd, 2023**. Applicants must upload the following application materials to the online portal (<https://mcphs.smapply.io>) no later than **Friday November 17th, 2023**:

- Letter of intent
- Curriculum vitae
- Unofficial college transcript
- Contact information for three references. References will receive an electronic recommendation form to complete separately.

Three recommendation evaluation forms must be submitted no later than **Monday, November 27th, 2023** via the online portal. This is NOT a letter of recommendation but an online form that the recommender will receive for completion from SMAApply.

## ROLLING APPLICATION REVIEW & INTERVIEWS

All submitted applications will be reviewed on a rolling basis. Interviews will also be offered on a rolling basis and opportunities are limited. Priority will be given to those applicants who apply early, well in advance of the deadline.

Rolling interviews will begin mid-October with pre-screens and a mixture of interview rounds, and will continue into December. Candidates will be notified if selected for an interview.

## ASHP MIDYEAR & ONSITE INTERVIEWS

The fellowship program will be conducting **in-person interviews** at the ASHP Midyear Clinical Meeting in Anaheim, CA. Applicants are strongly encouraged to attend. Candidates attending in-person will not be able to interview without registering for both ASHP and PPS. Please refer to the ASHP & PPS website for registration details.

Top candidates may be invited for interviews at the sponsoring company's location.

## OFFER DATES

Recognizing that the choice of a Post-Doctoral Industry Fellowship is an important decision, MCPHS in conjunction with the Alliance of Industry Fellowship Associates (AIFA), has agreed to extend offers for Fellowships no earlier than **December 13th, 2023**.

We see this respect for candidate choice as a common aspect of each of our Program's cultures. We hope that other academic and non-academic Fellowship Programs will respect this timeline to allow for best program fit for candidates.

## ONBOARDING

Final candidates will be required to go through additional screening / onboarding as required by MCPHS.

**FOR MORE INFORMATION, PLEASE EMAIL:**

[PharmD.Fellowships@alexion.com](mailto:PharmD.Fellowships@alexion.com)



MASSACHUSETTS COLLEGE of PHARMACY  
and HEALTH SCIENCES

**BOSTON CAMPUS**  
179 Longwood Avenue  
Boston, MA 02115-5896

**MANCHESTER CAMPUS**  
1260 Elm Street  
Manchester, NH 03101

**WORCESTER CAMPUS**  
19 Foster Street  
Worcester, MA 01608-1715



Alexion Pharmaceuticals, Inc.  
121 Seaport Boulevard  
Boston, MA 02210

Photos throughout this brochure were taken prior to the COVID-19 pandemic or from a safe social distance.